RPG Life Sciences Limited (BOM:532983)
India
· Delayed Price · Currency is INR | Market Cap | 41.78B |
| Revenue (ttm) | 6.53B |
| Net Income (ttm) | 1.83B |
| Shares Out | n/a |
| EPS (ttm) | 110.79 |
| PE Ratio | 22.80 |
| Forward PE | n/a |
| Dividend | 24.00 (0.95%) |
| Ex-Dividend Date | Jun 27, 2025 |
| Volume | 3,267 |
| Average Volume | 2,190 |
| Open | 2,522.10 |
| Previous Close | 2,525.90 |
| Day's Range | 2,498.45 - 2,567.00 |
| 52-Week Range | 1,540.00 - 2,976.70 |
| Beta | n/a |
| RSI | 59.98 |
| Earnings Date | Apr 28, 2025 |
About RPG Life Sciences
RPG Life Sciences Limited, an integrated pharmaceutical company, develops, manufactures, and markets branded formulations, generic, and synthetic active pharmaceutical ingredients (APIs) in India and internationally. The company offers synthetic APIs in various therapeutic categories, including immunosuppressants, anti-psychotic, anti-anginal, anthelmintics, anti-convulsant, and anti-spasmodic, etc. It also provides generics for immunosuppressant therapy; and finished dosage formulations for various therapies, which include nephrology, rheumato... [Read more]
Financial Performance
In 2024, RPG Life Sciences's revenue was 6.53 billion, an increase of 12.26% compared to the previous year's 5.82 billion. Earnings were 1.83 billion, an increase of 109.03%.
Financial StatementsNews
RPG Life Sciences shares surge nearly 8% after Q4 net profit jumps 786% on one-time land gain
Shares of RPG Life Sciences rose 7.64% to ₹2,277.60 on Monday, climbing ₹161.70 from the previous close of ₹2,115.90. The stock was among the top gainers on the NSE following the announcement of the c...
RPG Life Sciences surges 9.36% on robust Q3 FY25 earnings; net profit up 32% YoY
RPG Life Sciences Limited’s stock rallied 9.36% to ₹2,279.20 on the NSE as of 9:57 AM, driven by its strong Q3 FY25 results. The company reported a 31.99% year-on-year increase in net profit to ₹34.93...
Stocks in focus today, January 27, 2025: JK Cement, Balkrishna Industries, Shakti Pumps, Yes Bank, KEC International, Trident, RPG Life Sciences, Jubilant Pharmova
Several mid- and small-cap companies have released key updates today, focusing on their Q3 performance, acquisitions, and new business orders. JK Cement: Q3 sales volumes grew 5%, and the company anno...